A Clinical Evaluation of the Safety and Efficacy of Randomized Placebo Versus the 8-aminoquinoline Tafenoquine for Early Symptom Resolution in Patients With Mild to Moderate COVID 19 Disease and Low Risk of Disease Progression
Phase 2
Not yet recruiting
- Conditions
- SARS-CoV-2Severe Acute Respiratory Syndrome Coronavirus 2COVID 19 DiseaseMild to Moderate COVID 19 DiseaseInfectious Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-07-17
- Last Posted Date
- 2023-07-17
- Lead Sponsor
- 60P Australia Pty Ltd
- Target Recruit Count
- 148
- Registration Number
- NCT05947812
© Copyright 2025. All Rights Reserved by MedPath